Latar belakang: Kanker merupakan penyebab utama kematian di seluruh dunia menurut WHO 2018. Inflamasi kronis mendukung proses karsinogenesis. Parameter inflamasi berupa interleukin-17, nilai NLR, PLR, dan LMR menjadi acuan dalam menentukan tingkat inflamasi sistemik pada pasien kanker. Probiotik berperan pada tatalaksana kanker melalui efek imunomodulasi dan antiinflamasi. Tujuan penelitian ini adalah menganalisis pengaruh pemberian probiotik terhadap penurunan kadar interleukin-17 serum, penurunan nilai NLR dan PLR, serta peningkatan nilai LMR pada pasien kanker paru yang menjalani kemoterapi.

Metode: Uji klinis dengan quasi-experimental pretest dan posttest pada kelompok perlakuan dan kontrol pasien KPKBSK yang menjalani kemoterapi berbasis platinum minimal 1 siklus di RSUD Dr. Moewardi Surakarta pada bulan Januari sampai Maret 2023 dengan metode consecutive sampling. Subjek penelitian dibagi menjadi dua kelompok yaitu kelompok perlakuan yang diberikan kemoterapi dan probiotik, kelompok kontrol diberikan kemoterapi tanpa probiotik. Subjek penelitian dilakukan pengambilan darah vena dua kali untuk diperiksa kadar interleukin-17 serum, nilai NLR, PLR, dan LMR. Pengambilan darah vena dilakukan sehari sebelum kemoterapi dan 21 sampai 24 hari setelahnya.

Hasil: Sebanyak tiga puluh pasien kanker paru yang menjalani kemoterapi dilibatkan dalam penelitian ini. Kelompok perlakuan menunjukkan penurunan kadar interleukin-17 (-41,86±25,12), penurunan nilai NLR (-1,37±1,79), penurunan nilai PLR (-68,77±63,95), dan peningkatan nilai LMR (1,18±0,98), serta terdapat perbedaan yang signifikan dibandingkan dengan kontrol (p?0,05).

Simpulan: Terdapat perbedaan bermakna berupa penurunan kadar interleukin-17, penurunan nilai NLR dan PLR, serta peningkatan nilai LMR antara kelompok perlakuan yang diberikan probiotik dengan kelompok kontrol.

Kata kunci: probiotik, kemoterapi, interleukin-17, NLR, PLR, LMR.

ABSTRACT

Background: Cancer is the leading cause of death worldwide according to WHO 2018. Chronic inflammation supports the process of carcinogenesis. Inflammatory parameters such as interleukin-17, NLR, PLR, and LMR values ??are used as a reference in determining the level of systemic inflammation in cancer patients. Probiotics play a role in cancer management through their immunomodulating and anti-inflammatory effects. The purpose of this study was to analyze the effect of giving probiotics on decreasing serum interleukin-17 levels, decreasing NLR and PLR values, and increasing LMR values ??in lung cancer patients undergoing chemotherapy.

Methods: Clinical trials with quasi-experimental pretest and posttest in the treatment and control groups of NSCLC patients undergoing at least 1 cycles of platinum-based chemotherapy at RSUD Dr. Moewardi Surakarta from January to March 2023 using consecutive sampling method. The research subjects were divided into the treatment group was given chemotherapy and probiotics, the control group was given chemotherapy without probiotics. The research subjects were taken twice by venous blood sampling to check serum levels of interleukin-17, NLR, PLR, and LMR values. Venous blood sampling were done the day before chemotherapy and 21 up to 24 days after that.

Results: Thirty lung cancer patients undergoing chemotherapy were included in this study. The intervention group showed decreased levels of interleukin-17 (-41,86±25,12), decreased NLR values (-1,37±1,79), decreased PLR values (-68,77±3,95), increased LMR values ??(1,18±0,98), and there is a significant difference compared to the control (p ?0,05).

Conclusion: There were significant differences in the form of decreased interleukin-17 levels, decreased NLR and PLR values, and increased LMR values ??between the treatment group given probiotics and the control group.

Keywords: probiotic, chemotherapy, interleukin-17, NLR, PLR, LMR.